*ST華英(002321.SZ):部分股東持股比例被稀釋至5%以下
格隆匯1月6日丨*ST華英(002321.SZ)公佈,公司因執行《河南華英農業發展股份有限公司重整計劃》,以公司現有總股本534,291,100股為基數,按每10股轉增29.92股的比例實施資本公積轉增股本,共計轉增1,598,598,971股股票。轉增後,華英農業總股本由534,291,100股增加至2,132,890,071股。
根據中國證券登記結算有限責任公司深圳分公司於2021年12月31日出具的《發行人股本結構表》,本次轉增已實施完成,因此,河南潢川華英禽業總公司、河南農投金控股份有限公司、深圳盛合匯富二期股權投資合夥企業(有限合夥)持有公司股份比例被稀釋至5%以下。變動情況如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.